281 related articles for article (PubMed ID: 9103399)
1. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
[TBL] [Abstract][Full Text] [Related]
2. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
Agorastos T; Vaitsi V; Paschopoulos M; Vakiani A; Zournatzi-Koiou V; Saravelos H; Kostopoulou E; Constantinidis T; Dinas K; Vavilis D; Lolis D; Bontis J
Maturitas; 2004 Jun; 48(2):125-32. PubMed ID: 15172086
[TBL] [Abstract][Full Text] [Related]
3. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up.
Pérez-Medina T; Bajo J; Folgueira G; Haya J; Ortega P
Gynecol Oncol; 1999 May; 73(2):299-304. PubMed ID: 10329050
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of hyperplasia endometrium with GNRH agonists].
Radowicki S; Skórzewska K
Ginekol Pol; 2003 Sep; 74(9):836-9. PubMed ID: 14674133
[TBL] [Abstract][Full Text] [Related]
5. Digital morphometry of cytologic aspirate endometrial samples.
Mahovlić V; Ovanin-Rakić A; Skopljanac-Macina L; Barisić A; Rajhvajn S; Juric D; Projić IS; Ilić-Forko J; Babić D; Skrablin-Kucić S; Bozikov J
Coll Antropol; 2010 Mar; 34(1):45-51. PubMed ID: 20437635
[TBL] [Abstract][Full Text] [Related]
6. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices.
Perino A; Quartararo P; Catinella E; Genova G; Cittadini E
Acta Eur Fertil; 1987; 18(2):137-40. PubMed ID: 3115027
[TBL] [Abstract][Full Text] [Related]
7. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
8. [Conservative therapeutic possibilities in glandular or adenomatous endometrium hyperplasia].
Schindler AE
Zentralbl Gynakol; 1996; 118(6):359-64. PubMed ID: 8768014
[TBL] [Abstract][Full Text] [Related]
9. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
10. [Modern tendencies in treatment of atypical glandular hyperplasia--our and foreign experience].
Ivanov S; Kovachev E; Tsonev A; Abbud A
Akush Ginekol (Sofiia); 2010; 49(2):47-9. PubMed ID: 20734678
[TBL] [Abstract][Full Text] [Related]
11. GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells.
Nagai N; Oshita T; Mukai K; Shiroyama Y; Shigemasa K; Ohama K
Int J Mol Med; 2002 Nov; 10(5):593-7. PubMed ID: 12373298
[TBL] [Abstract][Full Text] [Related]
12. [Endometriosis: clinical, histological and morphometric findings before and after Gn-RH agonist therapy].
Ruwe M; Donhuijsen K; Regidor PA; Leder LD; Schindler AE
Zentralbl Gynakol; 1998; 120(8):391-8. PubMed ID: 9757546
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
[TBL] [Abstract][Full Text] [Related]
14. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
15. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
16. Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells.
Zhao LJ; Liu N; Li XP; Wang JL; Wei LH
Chin Med J (Engl); 2010 May; 123(9):1170-5. PubMed ID: 20529558
[TBL] [Abstract][Full Text] [Related]
17. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
19. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
20. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP.
Ravenna L; Salvatori L; Morrone S; Lubrano C; Cardillo MR; Sciarra F; Frati L; Di Silverio F; Petrangeli E
J Androl; 2000; 21(4):549-57. PubMed ID: 10901441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
